Skip to main content
An official website of the United States government

c-Met inhibitor JNJ-38877605

An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. c-Met inhibitor JNJ-38877605 selectively inhibits c-Met, a receptor tyrosine kinase (RTK) involved in cancer cell survival and invasiveness, and tumor angiogenesis. c-Met is also known as hepatocyte growth factor receptor (HGFR).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:JNJ-38877605
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search